Using its digital biology platform, Recursion is building a pipeline of drug candidates for diseases that don’t have approved therapies. At its foundation, the platform uses lab robotics and machine vision to capture changes in the morphology of cells as they’re exposed to toxins, pathogens, genetic changes, and small and large molecules. By pairing this phenomics data with large transcriptomic and proteomic datasets — and running other custom assays and animal studies — Recursion learns how drug candidates act on cells, and can advance the most promising candidates to clinical trials.
News & Insights
DCVC 2023 Q1 update
Confluent IPO: Data In (Upward) Motion
Protecting the Digital World Around Us: SentinelOne IPO
From Seed to IPO: Zymergen Brings Biofacturing Public
Using Biology-as-a-Platform to Move from Treatment to Cure
An Update on How Deep Tech is Arming the Fight Against COVID-19
Powering a Comprehensive Response to the COVID-19 Crisis Through Deep Tech
Solving the world’s hardest problems with Deep Tech: Request for Startups
DCVC leads $60 million Series B investment in Recursion Pharmaceuticals: Machine Vision & Robotics to Accelerate Drug Discovery
In The Media
Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data
Nvidia deepens bets on AI in drug discovery with Recursion investment
Nature Reviews highlights how companies like DCVC co Recursion are combining cell imaging and machine learning to search for new pharmaceuticals
ZDNet talks cell painting, explaining how Recursion Pharmaceuticals is combining sophisticated cell imaging with machine learning to find cures for diseases
Recursion Pharmaceuticals Raises $121m Series C to use AI to decode biology and radically improve lives
Explore Companies
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing